Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) is now available.
Nanjing Leads Biolabs Co., Ltd. announced that its drug candidate LBL-047 received Investigational New Drug (IND) approval from the National Medical Products Administration of China. LBL-047 is the first bispecific fusion protein targeting both plasmacytoid dendritic cells and B cells, showing potential as a first and best-in-class treatment for autoimmune diseases. The approval allows the company to conduct a Phase I clinical trial to assess the drug’s safety and efficacy in systemic lupus erythematosus patients. Additionally, Nanjing Leads Biolabs has partnered with Dianthus Therapeutics, granting them exclusive global rights to develop and commercialize LBL-047 outside Greater China, aiming to maximize its clinical and commercial potential.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a biotechnology company based in China, focusing on the development of innovative therapies for autoimmune diseases. The company specializes in creating bispecific fusion proteins, with a market focus on addressing unmet medical needs in autoimmune conditions.
Average Trading Volume: 686,593
Current Market Cap: HK$10.54B
Find detailed analytics on 9887 stock on TipRanks’ Stock Analysis page.